An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York on March 28, 2024.Shelby Knowles | Bloomberg | Getty ImagesEli Lilly said on Wednesday its weight-loss drug, Zepbound, used with psoriasis treatment Taltz, showed better results ⁠in patients with the skin disease and obesity in a late-stage ​study, compared ​to Taltz alone.The ​drugs showed greater improvement in skin symptoms and weight loss in the study of 274 patients. ⁠About ‌27.1% of patients who had received Taltz ⁠and Zepbound reached complete skin clearance and at least 10% weight loss, compared to 5.8% of patients treated with Taltz alone ‌at 36 weeks, meeting the main goal.Psoriasis is a chronic condition that causes itchy, scaly patches ​on the skin.Nearly all trial participants had psoriasis affecting sensitive areas such as the face, scalp or genitals, which are typically hard to ⁠treat, Lilly said.In the U.S., about 61% of people ‌with psoriasis also have obesity or ‌are overweight with at least one weight-related co-morbidity, Lilly said.Adverse events during the study were generally mild to moderate, Lilly ⁠said, adding that detailed results from the trial will ⁠be published in a peer-reviewed journal ⁠and discussed with regulators.In another late-stage study, 31.7% of patients who received Taltz plus Zepbound met ​the main goal ‌of the study of at least a 50% reduction in psoriatic arthritis disease activity and at least 10% weight loss after 36 weeks. That compared with 0.8% of patients who ​took Taltz alone and ‌met the same combined outcome.